The Muscular Dystrophy Association (MDA) and UF Innovate | The Hub resident client AavantiBio, a biotechnology company developing a gene-targeting therapy for Friedreich’s Ataxia (FA), announced the award of MDA Venture Philanthropy (MVP) funding totaling $1,076,232 to advance AavantiBio’s phase 2 clinical trial of a gene-replacement therapy for the disease. MVP is MDA’s drug development … Continue reading MDA Awards Venture Philanthropy Funding of More Than $1M to AavantiBio to Develop Gene-Targeting Therapy for Friedreich’s Ataxia